MIM
TENX icon

MetLife Investment Management’s Tenax Therapeutics TENX Stock Holding History

MetLife Investment Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+14,940
New +$191K ﹤0.01% 2377

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

MetLife Investment Management's TENX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Tenax Therapeutics (TENX) in Q2 2026: 14,940 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #2377 among its holdings.

111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • MetLife Investment Management held 14,940 shares of Tenax Therapeutics worth $217K as of Q2 2026.
  • Tenax Therapeutics was a new MetLife Investment Management position in Q2 2026.
  • Tenax Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2377 holding.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.